Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173654 | 1.00 | LMNA (0.53) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL4178992 | 0.90 | LMNA (0.53) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL4178993 | 0.90 | LMNA (0.53) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL4182040 | 0.89 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL4182042 | 0.89 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL2584577 | 0.89 | LMNA (0.58) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL4176169 | 0.87 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL4176167 | 0.87 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL2581175 | 0.87 | LMNA (0.56) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL11130612 | 0.86 | LMNA (0.58) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | INSTITUTE NATIONAL DE LA SAINTE ET DE LA RECHDERCHE MEDICALE (FR) | 2009-01-01 | — | — | US | disclosed |
| EP-1827457-A1 | URIDINE DERIVATIVES AS ANTIVIRAL DRUGS AGAINST A FLAVIVIRIDAE, ESPECIALLY HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006067606-A1 | URIDINE DERIVATIVES AS ANTIVIRAL DRUGS AGAINST A FLAVIVIRIDAE, ESPECIALLY HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-29 | — | — | WO | disclosed |
| EP-1674104-A1 | Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | NUDT1, UMPS, UPP1 | LMNA 4072/4885THRB 1136/4885SMN1; SMN2 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.